Last updated: 2026-10-13 23:11:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Tarsus Pharmaceuticals, Inc. (TARS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $70.86, with a market capitalisation of $3.42B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $53.89 to $91.53. This page covers its latest market performance, valuation, price trends and company information.
$3.42B | |
$74.50 | |
$91.53 | |
$10.80 | |
$74.40 | |
643.43K | |
827.06K | |
-- | |
$91.53 | |
$53.89 | |
-- | |
-- |
Tarsus Pharmaceuticals, Inc. (TARS) is trading at $70.26 in after-hours trading as of 2026-10-13 21:57:00, down 5.56% ($4.14) from the regular-session close of $74.40.
After-hours trading shows how investors are pricing TARS after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Tarsus Pharmaceuticals, Inc. (TARS) moved from $73.00 to $70.86, representing a decline of 2.93% ($2.14).
The stock traded between $70.37 and $77.16 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 815.24 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 45.1%
TARS is currently trading at $70.86, placing it 45.1% of the way from its 52-week low of $53.89 to its 52-week high of $91.53. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 370 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Tarsus Pharmaceuticals, Inc. (TARS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.